Business Wire

EGON-ZEHNDER

7.3.2024 09:31:29 CET | Business Wire | Press release

Share
New Global Survey from Egon Zehnder Reveals the CFO Role is Bigger Than Ever, “Super CFOs” Continue to Evolve Beyond Finance, Aspire to be CEO

Egon Zehnder, the world’s preeminent leadership advisory firm, today announced the results of a study that surveyed 581 CFOs worldwide to capture how the role of the chief financial officer has shifted over the past five years. The findings demonstrate a major evolution that has “Super CFOs” tackling new challenges, addressing new priorities, and aspiring even more for the CEO role.

Of the nearly 600 CFOs studied, 82% reported that their role has grown significantly, with the vast majority of CFOs citing how new complexities across environmental, social, and governance matters, mergers and acquisitions, and corporate strategy are driving sweeping change - and opportunity - within their role.

“Our study reveals a momentous evolution with ‘Super CFOs’ not just reacting to the changing business environment, but in fact driving it,” said Arun Dhingra, Global Head of Egon Zehnder’s CFO & Audit Chair Practice. “Through my work, I’ve witnessed this transformative era firsthand, and our CFO study reaffirms the reality that the complexities of the CFO role have propelled these leaders to the forefront of their organizations due to the profound shift in their priorities and substantial growth in their role.”

Guiding the Business: 82% of CFOs report they have taken on new responsibilities that were not part of their remit just five years ago

As business dynamics have changed over the past five years, so too has the nature of the CFO’s workload. When asked what new responsibilities have been added to their plate, CFOs ranked ESG, M&A, and corporate strategy as the top three – signaling not only a reaction to shifting industry and market priorities but new reliance upon CFOs as strategic partners to the CEO and the board. This drastic increase in scope is inspiring CFOs to consider their roster of priorities and what could be excluded from their remit in favor of more pressing tasks. As their mandates expand, nearly half (47%) of CFOs report needing to allocate more time to business strategy to meet the new expectations demanded from them.

Looking to the future, the trend of increased responsibilities is expected to continue. When asked about the competencies that will matter most over the next five years, CFOs ranked driving change, shaping strategy, and developing talent as the most important. In particular, female CFOs were adamant about driving change—57% named this the key competency compared to 40% of male CFOs.

Leading their People: Over 40% of CFOs say it is harder to attract top financial talent today compared to two years ago

While CFOs would like to allocate additional time to strategy and talent development, CFOs view finding talent and IT as least central to the future remit of the role. Two-fifths of CFOs agree that it’s harder to attract top financial talent today than it was two years ago.

Over half of CFOs surveyed are ensuring they’re building and developing the right bench by employing the following strategies – more open and honest feedback to the team, rotating top talent throughout various financial roles, and targeted development programs. CFOs largely agree the top two team members they rely on the most are the Head of FP&A and the Controller/CAO. For finance professionals aspiring to become a CFO, when reflecting on their first CFO role, respondents identified board interaction, external credibility with investors, and co-leadership of the organization with the CEO as key areas that required the most growth.

Managing their Careers: 62% of CFOs want to be chief executives at some point in their career, with 7 in 10 reporting they feel prepared to take on the role now

CFO sentiments are also shifting and expanding when it comes to personal career aspirations. While an expanded, more multifunctional CFO role may help them seize those new opportunities – nearly half say networking and visibility is a major barrier to becoming CEO. What’s more, 44% of CFOs are being approached more often for opportunities, a sign that the significant level of CFO departures seen in 2023 is not slowing down. Among CFOs who reported being approached the most, recruitment outreach is especially strong for female CFOs – women reported being reached out to more often (17%) when compared to men (12%), a sign that organizations are continuing to prioritize gender diversity within the C-Suite.

With growing competition for CFO talent, 60% of respondents say they value a high-quality executive team as well as growth prospects (for 45% of respondents) when considering whether to pursue a new opportunity. The focus on whom they’ll work with, over company valuation and revenue, signals that companies that are more intentional about executive development are better positioned to attract top talent than those that aren’t.

“Maintaining the role of corporate ‘Superhero’ is no easy feat,” said James Stark, lead author of the Super CFO Survey and consultant in the CFO & Audit Chair Practice at Egon Zehnder. “As signs point to the CFO role continuing to grow in complexity, financial leaders will need to keep growing their leadership skills to drive success in their current role – and to help them reach the next step in their career trajectory. From talent development to leading their organization's ESG initiatives, the role of the CFO today is a central figure in charting sustainable growth and ensuring organizational resilience in any industry.”

For more information on Egon Zehnder’s services and the study cited in this press release, please visit www.egonzehnder.com/the-super-cfo.

About Egon Zehnder

Egon Zehnder is the world’s preeminent leadership advisory firm, inspiring leaders to navigate complex questions with human answers. Our 600 consultants across 64 offices and 36 countries are former industry and functional leaders who collaborate seamlessly to deliver the full power of the Firm to every client, every time. We believe that together we can transform people, organizations and the world through leadership. For more information, visit www.egonzehnder.com and follow us on LinkedIn and X.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240306711015/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye